Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer

3Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: To explore the maximum tolerated dose (MTD) and evaluate the safety of dose escalation using hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) concurrent with chemotherapy for unresectable stage III non-small cell lung cancer (NSCLC). Methods: Four escalating radiation dose levels were used. This study included 25 patients with previously untreated NSCLC who received six concurrent weekly chemotherapy cycles comprising cisplatin and docetaxel. Dose-limiting toxicity (DLT) was defined as any acute toxicity that interrupted radiotherapy for more than 1 week. MTD was defined as the highest dose level that didn’t induce DLT or grade 5 toxicity in two patients. Results: All 25 patients received the prescribed escalating radiation dose from the start dose up to LEVEL 4. Two patients experienced DLT at dose LEVEL 4. One patient died because of upper gastrointestinal hemorrhage within 6 months after radiotherapy, whereas another patient among the additional five patients died because of grade 5 radiation pneumonitis within 2 months after radiotherapy. Dose LEVEL 3 was defined as MTD. The 1- and 2-year local controls were 82.8 and 67.8%, respectively. The median progression-free survival was 15.4 months, whereas the median overall survival was 27.3 months. Conclusions: Dose escalation was safely achieved up to LEVEL 3 [the planning gross target volume (PTVG) 60.5 Gy/22 Fx, 2.75 Gy/Fx; the planning clinical target volume (PTVC) 49.5 Gy/22 Fx] using SIB-IMRT concurrently with chemotherapy for unresectable stage III NSCLC, and the acute toxicities were generally well tolerated. Further prospective studies on long-term outcomes and late toxicities are warranted. Trial registration: Retrospective registration, ChiCTR1900027290(08/11/2019).

References Powered by Scopus

Cancer statistics in China, 2015

16902Citations
N/AReaders
Get full text

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

3514Citations
N/AReaders
Get full text

Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC

2252Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Personalized mid-course FDG-PET based adaptive treatment planning for non-small cell lung cancer using machine learning and optimization

6Citations
N/AReaders
Get full text

Daily CBCT-based dose calculations for enhancing the safety of dose-escalation in lung cancer radiotherapy

1Citations
N/AReaders
Get full text

Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety-Part 2. Lung (non-small cell lung cancer)

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zhang, Q., Cai, X. W., Feng, W., Yu, W., & Fu, X. L. (2022). Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer. BMC Cancer, 22(1). https://doi.org/10.1186/s12885-021-09099-3

Readers over time

‘22‘23‘240481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 1

33%

Environmental Science 1

33%

Engineering 1

33%

Save time finding and organizing research with Mendeley

Sign up for free
0